Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
COR Stock Forecast 2025-2026
$361.94
Current Price
$70.17B
Market Cap
Buy 11
Hold 4
Sell 1
Wall St Analyst Ratings
Distance to COR Price Targets
+15.2%
To High Target of $417.00
+9.8%
To Median Target of $397.50
-17.1%
To Low Target of $300.00
COR Price Momentum
+0.3%
1 Week Change
+13.2%
1 Month Change
+50.7%
1 Year Change
+61.1%
Year-to-Date Change
-1.9%
From 52W High of $369.00
+61.6%
From 52W Low of $223.92
📊 TOP ANALYST CALLS
Did COR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cencora is one of their latest high-conviction picks.
Latest COR Stock Price Targets & Analyst Predictions
Based on our analysis of 30 Wall Street analysts, COR has a bullish consensus with a median price target of $397.50 (ranging from $300.00 to $417.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $361.94, the median forecast implies a 9.8% upside. This outlook is supported by 11 Buy, 4 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Lisa Gill at JP Morgan, projecting a 15.2% upside. Conversely, the most conservative target is provided by Jonathan Petersen at Jefferies, suggesting a 17.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COR Analyst Ratings
11
Buy
4
Hold
1
Sell
COR Price Target Range
Low
$300.00
Average
$397.50
High
$417.00
Current: $361.94
Latest COR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 11, 2025 | JP Morgan | Lisa Gill | Overweight | Maintains | $417.00 |
| Nov 11, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $405.00 |
| Nov 10, 2025 | TD Cowen | Charles Rhyee | Buy | Maintains | $400.00 |
| Nov 7, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $415.00 |
| Nov 6, 2025 | Mizuho | Steven Valiquette | Outperform | Maintains | $380.00 |
| Nov 6, 2025 | Baird | David Rodgers | Outperform | Maintains | $395.00 |
| Oct 30, 2025 | Mizuho | Steven Valiquette | Outperform | Maintains | $340.00 |
| Oct 27, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $380.00 |
| Oct 16, 2025 | Mizuho | Steven Valiquette | Outperform | Maintains | $334.00 |
| Aug 13, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $354.00 |
| Jul 16, 2025 | Morgan Stanley | Erin Wright | Equal-Weight | Maintains | $330.00 |
| Jun 30, 2025 | Jefferies | Jonathan Petersen | Hold | Maintains | $300.00 |
| Jun 3, 2025 | Wells Fargo | Stephen Baxter | Overweight | Upgrade | $337.00 |
| May 8, 2025 | Citigroup | Michael Rollins | Buy | Maintains | $355.00 |
| May 8, 2025 | Baird | David Rodgers | Outperform | Maintains | $350.00 |
| Apr 29, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $335.00 |
| Apr 11, 2025 | B of A Securities | Michael Funk | Neutral | Maintains | $285.00 |
| Mar 14, 2025 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $274.00 |
| Feb 6, 2025 | Evercore ISI Group | John Belton | Outperform | Maintains | $280.00 |
| Jan 29, 2025 | Wells Fargo | Eric Luebchow | Equal-Weight | Maintains | $251.00 |
Cencora Inc. (COR) Competitors
The following stocks are similar to Cencora based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cencora Inc. (COR) Financial Data
Cencora Inc. has a market capitalization of $70.17B with a P/E ratio of 45.9x. The company generates $321.33B in trailing twelve-month revenue with a 0.5% profit margin.
Revenue growth is +5.9% quarter-over-quarter, while maintaining an operating margin of +1.1% and return on equity of +123.8%.
Valuation Metrics
Market Cap
$70.17B
Enterprise Value
$73.77B
P/E Ratio
45.9x
PEG Ratio
0.0x
Price/Sales
0.2x
Growth & Margins
Revenue Growth (YoY)
+5.9%
Gross Margin
N/A
Operating Margin
+1.1%
Net Margin
+0.5%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+6.2%
Current Ratio
0.9x
Debt/Equity
438.5x
ROE
+123.8%
ROA
+3.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cencora Inc. (COR) Business Model
About Cencora Inc.
What They Do
Pharmaceutical sourcing and distribution services company.
Business Model
Cencora Inc. generates revenue by providing logistics, consulting, and innovative solutions to enhance pharmaceutical supply chain operations for healthcare providers, including hospitals and pharmacies. Their model relies on a vast network of distribution centers to ensure efficient delivery of medications and healthcare products.
Additional Information
With a strong global presence, Cencora Inc. partners with pharmaceutical manufacturers to streamline operations, reduce costs, and improve patient outcomes. The company emphasizes sustainability and innovation while being headquartered in Conshohocken, Pennsylvania.
Company Information
Sector
Communication Services
Industry
Internet Content & Information
Employees
187,103
CEO
Mr. Sundar Pichai
Country
United States
IPO Year
2023
Website
abc.xyzCencora Inc. (COR) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Here's Why Cencora (COR) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Nov 14, 2025
By Zacks Equity Research
Tale of the Tape
Why Cencora (COR) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Nov 13, 2025
By Zacks Equity Research
Tale of the Tape
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Nov 07, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Cencora plans to invest over $1 billion by 2030 to expand its U.S. network, projecting adjusted profits for next year to exceed Wall Street forecasts.
Why It Matters
Cencora's $1 billion investment signals growth potential and confidence in profitability, likely boosting investor sentiment and stock performance.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Cencora, Inc. (COR) will host its Q4 2025 earnings call on November 5, 2025, at 8:30 AM EST, featuring key executives and multiple analysts from major financial institutions.
Why It Matters
Cencora's Q4 earnings call will provide insights into its financial performance and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Cencora is rated a Buy with a target price of $392, supported by strong fundamentals, stable cash flows, low debt, and double-digit profit growth in specialty drugs.
Why It Matters
Cencora's strong fundamentals, stable cash flows, and positive earnings growth signal reliability, making it appealing for conservative, long-term investment strategies.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Cencora, Inc. (NYSE: COR) reported Q4 FY2025 revenue of $83.7 billion, up 5.9%. Fiscal year revenue totaled $321.3 billion, with GAAP EPS at $(1.75), down from $0.02 year-over-year.
Why It Matters
Cencora's revenue growth indicates strong market performance, but the negative EPS raises concerns about profitability, impacting investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cencora (COR) reported quarterly earnings of $3.84 per share, surpassing the Zacks Consensus Estimate of $3.79 and increasing from $3.34 per share year-over-year.
Why It Matters
Cencora's earnings beat expectations and show year-over-year growth, indicating strong financial performance that could boost investor confidence and stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Cencora's (COR) revenue and EPS for Q3 2025 are available, but key metrics should be compared to Wall Street estimates and previous year's figures for a comprehensive view.
Why It Matters
Cencora's performance relative to Wall Street estimates and year-ago figures impacts investor sentiment, influencing stock price movements and future growth expectations.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About COR Stock
What is Cencora Inc.'s (COR) stock forecast for 2026?
Based on our analysis of 30 Wall Street analysts, Cencora Inc. (COR) has a median price target of $397.50. The highest price target is $417.00 and the lowest is $300.00.
Is COR stock a good investment in 2026?
According to current analyst ratings, COR has 11 Buy ratings, 4 Hold ratings, and 1 Sell ratings. The stock is currently trading at $361.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for COR stock?
Wall Street analysts predict COR stock could reach $397.50 in the next 12 months. This represents a 9.8% increase from the current price of $361.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cencora Inc.'s business model?
Cencora Inc. generates revenue by providing logistics, consulting, and innovative solutions to enhance pharmaceutical supply chain operations for healthcare providers, including hospitals and pharmacies. Their model relies on a vast network of distribution centers to ensure efficient delivery of medications and healthcare products.
What is the highest forecasted price for COR Cencora Inc.?
The highest price target for COR is $417.00 from Lisa Gill at JP Morgan, which represents a 15.2% increase from the current price of $361.94.
What is the lowest forecasted price for COR Cencora Inc.?
The lowest price target for COR is $300.00 from Jonathan Petersen at Jefferies, which represents a -17.1% decrease from the current price of $361.94.
What is the overall COR consensus from analysts for Cencora Inc.?
The overall analyst consensus for COR is bullish. Out of 30 Wall Street analysts, 11 rate it as Buy, 4 as Hold, and 1 as Sell, with a median price target of $397.50.
How accurate are COR stock price projections?
Stock price projections, including those for Cencora Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 15, 2025 9:56 AM UTC